Navigation Links
INTUNIV in Medical News

Shire's INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms

San Francisco, CA May 18, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met i...

Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms

WASHINGTON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medic...

FDA Approves INTUNIV (guanfacine) for the Treatment of ADHD

Shire announced today that it has received an approvable letter from the US Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant selective alpha-2A-receptor agonist, which has been studied in children and adolescent...
INTUNIV in Medical Technology

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

...The FDA did not identify safety concerns regarding intuniv in the Complete Response letter or request new cli...h an important new treatment option." About intuniv intuniv is being studied for the treatment of ADHD in chil...

Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms

...aceutical company, today announced new findings on intuniv (guanfacine) extended release, a selective alpha-2...ry objective, which was to evaluate the effects of intuniv on oppositional symptoms in children aged 6 to 12 ...de additional support for the clinical efficacy of intuniv for treating ADHD in this patient population." ...

Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose

...tivity Disorder (ADHD). The data demonstrated that intuniv showed significant efficacy in reducing ADHD sympt...s for all weight adjusted dose groups treated with intuniv when compared to placebo for all time periods (at ...m the analysis showed that all groups treated with intuniv responded to the medication in a shorter time peri...
INTUNIV in Biological Technology

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... Prescription Drug User Fee Act date ("PDUFA") for intuniv was July 27, 2009. Shire has received a Comp...rican countries during 2009 and 2010; - intuniv for the treatment of ADHD in children and adolesce... 158.7 28% 136.4 19% intuniv license payment (36.9) - ...

Shire begins the year with a strong performance

...half of the year we are anticipating the launch of intuniv and the completion of several Phase 2 and Phase 3 ... The Prescription Drug User Fee Act date for intuniv is July 26, 2009 and the launch of intuniv in the US is anticipated for the fourth quar...

Publication of Shire plc's Annual Report 2008

...r 2007 and in the EU via the decentralized procedure, with the Netherlands as the reference member state in December 2007. Reviews are ongoing. intuniv for ADHD in US In June 2007 Shire received an approvable letter from the FDA for INTUNIV. Shire is conducting additional clinical work which is...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

...- FIRAZYR (icatibant) for the symptomatic treatment of acute attacks of HAE in certain European and Latin American countries during 2009; - intuniv (guanfacine extended release) for use in the treatment of ADHD in children and adolescents in the US in the second half of 2009; - FO...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

...NIV(TM) - ADHD - On May 8, 2008 Shire announced pivotal trial results for intuniv which is in registration in the US. The data demonstrated that intuniv has significant efficacy in reducing ADHD symptoms for patients taking t...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

...two years: - MEZAVANT in the EU during 2008; - VYVANSE for use in adult patients in the US in Q2 2008; - DAYTRANA in the EU during H1 2009; - intuniv in the US during H2 2009; and - FOSRENOL in the pre-dialysis Chronic Kidney Disease ("CKD") market in the US during 2009. 2008 Financial Outlook ...

Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

...ada during 2008; - VYVANSE for use in adult patients in the US in Q2 2008 (PDUFA date April 28, 2008); - DAYTRANA in the EU during H1 2009; - intuniv in the US during H2 2009; and - FOSRENOL in the CKD market in the US during 2009. Financial Outlook Shire's business continues to perform strongl...
Other Tags
(Date:12/17/2014)... (HealthDay News) -- Expectant parents should leave prenatal picture-taking ... recommends. Use of ultrasound imaging and heartbeat monitors ... risk-free, the agency warns. "Although there is ... ultrasound imaging and heartbeat monitors, prudent use of these ... Vaezy, an FDA biomedical engineer, said in an agency ...
(Date:12/17/2014)... Amy Norton HealthDay ... Yoga has long been believed to improve overall health, but ... also help the heart, a new review finds. In ... such as brisk walking, said lead researcher Paula Chu, a ... The review, of 37 clinical trials, found that people ...
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic ... JM Ocean Avenue has secured exclusive benefit to the ... system. JM Ocean Avenue is a direct sales ... Avenue and JM International, with partial ownership coming from ... company. , “After nearly 2 decades of servicing the ...
(Date:12/15/2014)... MD (PRWEB) December 15, 2014 ... services today released “ Social Media Cheat Sheets ,” ... a community that drives results on the top ten ... marketing program. It helps drive awareness, engagement, and customer ... For marketers to make an impact on new networks ...
(Date:12/15/2014)... Dallas,TX (PRWEB) December 15, 2014 The increase ... is one of the main factors which is contributing to ... used for the diagnosis and treatment of hearing loss and ... comprises of three parts - microphone, speaker and amplifier. The ... growth rate of 6.01% during the period from 2014 to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
Other Contents